Gefapixant in two randomised dose-escalation studies in chronic cough

2020133 citationsJournal Articlebronze Open Access

Authors

John A. Smith · Manchester Academic Health Science Centre

Michael M. Kitt · Merck & Co., Inc., Rahway, NJ, USA (United States)

P. Butera · Merck & Co., Inc., Rahway, NJ, USA (United States)

Steven A. Smith · Merck & Co., Inc., Rahway, NJ, USA (United States)

Yuping Li

Zhi Jin Xu · Merck & Co., Inc., Rahway, NJ, USA (United States)

Kimberley Holt · Manchester Academic Health Science Centre

Abstract

P2X3 antagonism with gefapixant demonstrates anti-tussive efficacy and improved tolerability at lower doses than previously investigated. Studies of longer duration are warranted.

Topics & Keywords

Respiratory and Cough-Related Research Asthma and respiratory diseases Pediatric health and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Respiratory Journal

Volume 55, Issue 3, pp. 1901615-1901615

DOI: 10.1183/13993003.01615-2019

Field-Weighted Citation Impact: 13.48